ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
Get Alerts IMGN Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
- Cowen 43rd Annual Health Care Conference
March 8 at 9:10am ET
- Barclays Global Healthcare Conference
March 15 at 10:15am ET
A webcast of each presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005317/en/
INVESTOR RELATIONS
ImmunoGen
Anabel Chan
781-895-0600
[email protected]
MEDIA
ImmunoGen
Courtney O'Konek
781-895-0600
[email protected]
OR
FTI Consulting
Robert Stanislaro
212-850-5657
[email protected]
Source: ImmunoGen, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Formosa Plastics Corporation, U.S.A. Announces Merger With Formosa Industries Corporation
- TaqFlow Emerges to Overhaul Central Asian Cross-Border Payments
- Dime City Apparel Hits Major Engagement Milestones Through Its Sub‑Brand, Dime City Pretty, on YouTube Shorts
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Barclays, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share